Tirzepatide vs Cagrilintide

Tirzepatide vs Cagrilintide: Overview

Tirzepatide and cagrilintide represent two distinct pharmacological approaches to metabolic disease research that have generated significant scientific interest. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, while cagrilintide is a long-acting amylin analogue. Both compounds have emerged from efforts to develop next-generation peptide therapies that address obesity and related metabolic conditions through complementary hormonal pathways.

The comparison between cagrilintide vs tirzepatide is particularly relevant for researchers studying multi-receptor targeting strategies. While tirzepatide acts on incretin receptors involved in glucose homeostasis and appetite regulation, cagrilintide mimics the satiety hormone amylin, which is co-secreted with insulin from pancreatic beta cells. The distinct mechanisms of these two compounds have prompted considerable interest in understanding how they differ in efficacy, safety, and clinical potential.

Researchers investigating tirzepatide vs cagrilintide are often interested in the broader question of which hormonal pathways offer the most promising targets for metabolic disease. Both agents have advanced through clinical development with compelling trial data, though they target fundamentally different receptor systems. This comparison examines the available evidence for each compound across key pharmacological parameters.

Mechanism of Action

Tirzepatide functions as a dual incretin receptor agonist, simultaneously activating both GIP and GLP-1 receptors. The GLP-1 receptor component promotes insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic centres involved in appetite regulation. The GIP receptor component appears to enhance the metabolic effects of GLP-1 receptor activation and may independently influence adipose tissue metabolism and energy balance. Research suggests that the dual agonism of tirzepatide produces effects that exceed those observed with selective GLP-1 receptor agonists alone (Son et al., 2026).

Cagrilintide, by contrast, is a long-acting analogue of the hormone amylin (also known as islet amyloid polypeptide, or IAPP). Amylin is co-secreted with insulin from pancreatic beta cells and plays a role in glycaemic regulation by slowing gastric emptying, suppressing postprandial glucagon secretion, and promoting satiety through brainstem signalling pathways. Cagrilintide was engineered with modifications to extend its half-life significantly beyond that of native amylin, enabling once-weekly subcutaneous administration (Kruse et al., 2021). The amylin receptor system represents a distinct neurohormonal pathway from the incretin system targeted by tirzepatide, which is why the combination of cagrilintide with semaglutide (known as CagriSema) has also been investigated as a complementary dual-pathway approach.

When comparing cagrilintide vs tirzepatide at the receptor level, the key distinction lies in their target receptors and downstream signalling cascades. Tirzepatide engages two incretin receptors (GIP and GLP-1), while cagrilintide activates amylin receptors, which are heterodimeric complexes formed by the calcitonin receptor and receptor activity-modifying proteins (RAMPs). These fundamentally different receptor targets mean that the two compounds influence energy balance and glucose homeostasis through largely non-overlapping mechanisms.

Clinical Evidence

Tirzepatide has been evaluated in extensive phase 3 clinical trial programmes. The SURPASS programme assessed tirzepatide in individuals with type 2 diabetes, demonstrating substantial reductions in glycated haemoglobin (HbA1c) and body weight across multiple trials. The SURMOUNT programme subsequently evaluated tirzepatide specifically for weight management. In the landmark SURMOUNT-1 trial, tirzepatide demonstrated mean weight reductions of up to 22.5% at the highest evaluated dose after 72 weeks, findings that have been described as unprecedented for a single pharmacological agent (Jastreboff et al., 2025). Long-term extension data from SURMOUNT-1 have continued to show sustained weight reduction over 176 weeks (Heerspink et al., 2026).

Clinical evidence for cagrilintide includes a phase 2 trial in individuals with overweight or obesity, which demonstrated dose-dependent weight reductions. In this 26-week study, the highest dose of cagrilintide achieved a mean weight loss of approximately 10.8% compared to 3.0% with placebo (Lau et al., 2021). Cagrilintide has also been studied in combination with semaglutide as CagriSema. The REDEFINE 1 phase 3 trial of CagriSema in adults with overweight or obesity demonstrated clinically meaningful weight reduction and improvements in cardiometabolic parameters, with the combination showing blood pressure-lowering effects (Verma et al., 2026; Garvey et al., 2025).

It should be noted that direct head-to-head clinical trials comparing tirzepatide vs cagrilintide as monotherapies have not been conducted. Available comparisons rely on cross-trial analyses, which carry inherent limitations due to differences in study populations, trial design, endpoints, and duration. Network meta-analyses examining GLP-1-based therapies have included both compounds, though such indirect comparisons should be interpreted with appropriate caution (Sinha et al., 2025).

Efficacy Comparison

Based on available trial data, tirzepatide has demonstrated larger absolute weight reductions in clinical studies than cagrilintide monotherapy. In the SURMOUNT programme, tirzepatide at the highest dose achieved mean weight loss exceeding 20% from baseline, while cagrilintide monotherapy in its phase 2 trial achieved approximately 10.8% over a shorter treatment duration. However, it is important to emphasise that these figures come from separate trials with different populations, durations, and designs, making direct numerical comparison methodologically limited.

The combination of cagrilintide with semaglutide (CagriSema) has shown weight reduction outcomes that appear broadly comparable to tirzepatide, suggesting that the amylin pathway targeted by cagrilintide provides meaningful additive benefit when combined with GLP-1 receptor agonism. In the REDEFINE programme, CagriSema demonstrated weight loss in the range of 20-25% in some trial arms (Garvey et al., 2025; Davies et al., 2025). This has prompted researchers to compare tirzepatide vs cagrilintide not only as individual compounds but also in terms of their respective multi-receptor strategies.

For glycaemic endpoints, tirzepatide has demonstrated robust HbA1c reductions in individuals with type 2 diabetes across the SURPASS programme. Cagrilintide’s glycaemic effects have been less extensively characterised in isolation, though the amylin pathway is known to influence postprandial glucose excursions through glucagon suppression and gastric motility modulation.

Safety and Tolerability

The most commonly reported adverse events with tirzepatide in clinical trials have been gastrointestinal in nature, including nausea, diarrhoea, vomiting, and constipation. These events were generally mild to moderate in severity, most frequent during dose escalation periods, and tended to diminish over time. Discontinuation rates due to adverse events in the SURMOUNT programme were relatively low, and the overall safety profile has been characterised as consistent with the GLP-1 receptor agonist class (Caruso et al., 2024).

Cagrilintide has similarly shown a predominantly gastrointestinal adverse event profile in clinical trials. Nausea was the most frequently reported event, with injection site reactions also noted. In the phase 2 trial, gastrointestinal adverse events appeared to be dose-dependent. The QTc evaluation of cagrilintide demonstrated no clinically relevant prolongation, providing reassurance regarding cardiac safety (Gabe et al., 2024). When used in combination as CagriSema, the adverse event profile has remained consistent with gastrointestinal complaints being the primary tolerability concern.

Both compounds carry class-related theoretical concerns, including potential effects on the pancreas and thyroid. Tirzepatide carries warnings regarding medullary thyroid carcinoma risk based on preclinical findings in rodents, consistent with other GLP-1 receptor agonists. Cagrilintide, acting through the amylin pathway, has a distinct preclinical safety profile. Long-term safety data continue to accumulate for both agents.

Pharmacokinetics

Tirzepatide is administered as a once-weekly subcutaneous injection. It has a half-life of approximately 5 days (roughly 120 hours), which supports the weekly dosing schedule. Tirzepatide is formulated as a single-molecule dual agonist, meaning both GIP and GLP-1 receptor activity are contained within one peptide chain. Bioavailability following subcutaneous injection is high, and the compound exhibits linear pharmacokinetics across the clinical dose range.

Cagrilintide is also administered via once-weekly subcutaneous injection. It was specifically engineered for extended duration of action through modifications to the native amylin sequence, including acylation with a fatty diacid side chain and amino acid substitutions that enhance albumin binding and resist enzymatic degradation. These modifications extend the half-life to approximately 160 hours (roughly 7 days), supporting weekly administration (Kruse et al., 2021). The pharmacokinetic profile of cagrilintide demonstrates steady-state concentrations achieved after approximately 4-5 weekly doses.

Both tirzepatide and cagrilintide are subcutaneous injectables requiring refrigerated storage. Neither compound is currently available as an oral formulation, though oral delivery of peptide therapeutics remains an active area of research across the metabolic disease field. The similar dosing frequencies of the two agents have practical implications for research protocols and potential combination strategies.

Current Research Status

Tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for weight management) has received regulatory approval in multiple jurisdictions, including FDA approval in the United States. It is approved for glycaemic control in type 2 diabetes and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Ongoing clinical programmes continue to evaluate tirzepatide in additional indications, including heart failure, obstructive sleep apnoea, and cardiovascular outcomes (Malhotra et al., 2026; Lam et al., 2025).

Cagrilintide is currently in late-stage clinical development, primarily as part of the CagriSema combination with semaglutide. The REDEFINE phase 3 programme has produced results for the cagrilintide-semaglutide combination in both obesity and type 2 diabetes populations. Cagrilintide has not been approved as a standalone therapy, and its clinical development path is closely linked to the CagriSema combination programme. Regulatory submissions for CagriSema are anticipated based on the completed phase 3 data.

The competitive landscape between these agents reflects broader industry trends toward multi-receptor targeting in metabolic disease. Research comparing cagrilintide vs tirzepatide is likely to continue as post-marketing data accumulate for tirzepatide and as cagrilintide-based combinations progress toward potential regulatory decisions. Future studies may also explore whether sequential or combination use of incretin and amylin pathway agents could offer complementary benefits.

Summary

Tirzepatide and cagrilintide represent two pharmacologically distinct approaches to metabolic disease research. Tirzepatide is a dual GIP/GLP-1 receptor agonist with robust clinical evidence demonstrating significant weight reduction and glycaemic improvement, now approved for clinical use. Cagrilintide is a long-acting amylin analogue that targets a separate neurohormonal pathway involved in satiety and glucose regulation, primarily advancing through clinical development as part of the CagriSema combination. While direct head-to-head comparisons between tirzepatide vs cagrilintide are not available, the available evidence suggests both compounds produce clinically meaningful metabolic effects through their respective mechanisms. The key differentiators include receptor targets (incretin vs amylin pathways), regulatory status (approved vs investigational), and clinical development strategy (standalone vs combination-focused). Ongoing research continues to define the relative positions of these agents in the evolving landscape of metabolic therapeutics.

References

• Son JW et al. (2026). Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocrine Reviews. PMID: 41054801
• Kruse T et al. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. PMID: 34288673
• Jastreboff AM et al. (2025). Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England Journal of Medicine. PMID: 39536238
• Lau DCW et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet. PMID: 34798060
• Garvey WT et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. PMID: 40544433
• Davies MJ et al. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England Journal of Medicine. PMID: 40544432
• Verma S et al. (2026). CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. PMID: 41328546
• Gabe MBN et al. (2024). Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes, Obesity & Metabolism. PMID: 39279639
• Sinha B et al. (2025). Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight. Obesity. PMID: 40685589
• Caruso I et al. (2024). Incretin-based therapies for the treatment of obesity-related diseases. npj Metabolic Health and Disease. PMID: 40604322
• Heerspink HJL et al. (2026). Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 Weeks. Diabetes, Obesity & Metabolism. PMID: 41796090
• Malhotra A et al. (2026). Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nature Medicine. PMID: 41540105
• Lam CSP et al. (2025). Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity. PMID: 40545827